Sankyo's Antihypertensive Agent, ARB Olmesartan to Be Available in Central and South America.Tokyo, Japan, Aug 8, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sankyo announced on August 5 that it has signed a licensing agreement with Schering-Plough for its proprietary antihypertensive antihypertensive /an·ti·hy·per·ten·sive/ (-ten´siv) counteracting high blood pressure, or an agent that does this. an·ti·hy·per·ten·sive adj. Reducing high blood pressure. n. agent, olmesartan, an angiotensin II angiotensin II n. An octapeptide that is a potent vasopressor and a powerful stimulus for production and release of aldosterone from the adrenal cortex. receptor blocker. Under the terms of the agreement, Schering-Plough will exclusively sell the agent in Argentina, Boilvia, Chile, Paraguay, Peru and Uruguay. In addition, Sankyo will allow Schering-Plough to co-market the agent in Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Venezuela. Olmesartan is currently marketed in about 30 countries around the world. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion